Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors

被引：22

作者：

Cardinale, Jens ^{[1
]}

Roscher, Mareike ^{[1
]}

Schaefer, Martin ^{[1
]}

Geerlings, Max ^{[1
]}

Benesova, Martina ^{[1
]}

Bauder-Wuest, Ulrike ^{[1
]}

Remde, Yvonne ^{[1
]}

Eder, Matthias ^{[1
]}

Novakova, Zora ^{[2
]}

Motlova, Lucia ^{[2
]}

Barinka, Cyril ^{[2
]}

Giesel, Frederik L. ^{[3
]}

Kopka, Klaus ^{[4
]}

机构：

[1] German Canc Res Ctr, Div Radiopharmaceut Chem, D-69120 Heidelberg, Germany

[2] Czech Acad Sci, Lab Struct Biol, Inst Biotechnol, Vestec 25250, Czech Republic

[3] Univ Hosp Heidelberg, Dept Nucl Med, D-69120 Heidelberg, Germany

[4] Helmholtz Zentrum Dresden Rossendorf, Inst Radiopharmaceut Canc Res, D-01328 Dresden, Germany

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2020年 / 63卷 / 19期

关键词：

GLUTAMATE-CARBOXYPEPTIDASE-II; UREA-BASED INHIBITORS; PROSTATE-CANCER; PRECLINICAL EVALUATION; RADIATION-DOSIMETRY; DIAGNOSIS; LIGAND; PET/CT; F-18-PSMA-1007; BIODISTRIBUTION;

D O I：

10.1021/acs.jmedchem.9b01479

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer. In the present work, we report on the synthesis and preclinical evaluation of a series of F-18-labeled PSMA ligands for diagnostic application based on the theragnostic ligand PSMA-617. By applying modifications to the linker structure, insight into the structure-activity relationship could be gained, highlighting the importance of hydrophilicity and stereoselectivity on interaction with PSMA and hence the biodistribution. Selected compounds were co-crystallized with the PSMA protein and analyzed by X-rays with mixed results. Among these, PSMA-1007 (compound 5) showed the best interaction with the PSMA protein. The respective radiotracer [F-18]PSMA-1007 was translated into the clinic and is, in the meantime, subject of advanced clinical trials.

引用

页码：10897 / 10907

页数：11

共 50 条

[21] Synthesis and evaluation of an 18F-labeled PSMA-targeting tracer for imaging prostate cancer with positron emission tomography
Lu, Kelly
Zhang, Chengcheng
Zhang, Zhengxing
Merkens, Helen
Wilson, Ryan
Colpo, Nadine
Benard, Francois
Lin, Kuo-Shyan
NUCLEAR MEDICINE AND BIOLOGY, 2023, 126 : S86 - S87
[22] An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 During the First Year of Application
Dietlein, Felix
Hohberg, Melanie
Kobe, Carsten
Zlatopolskiy, Boris D.
Krapf, Philipp
Endepols, Heike
Taeger, Philipp
Hammes, Jochen
Heidenreich, Axel
Neumaier, Bernd
Drzezga, Alexander
Dietlein, Markus
JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (02) : 202 - 209
[23] Impact of dual phase F-18 labeled PSMA-1007 PET/CT on local prostatic lesions: Is it worthy?
Moustafa, Shymaa
Riad, Ahmed
JOURNAL OF NUCLEAR MEDICINE, 2024, 65
[24] A high affinity 18F-labeled phosphoramidate peptidomimetic inhibitor as a PSMA-targeted PET imaging agent for prostate cancer
Ganguly, Tanushree
Dannoon, Shorouk
Geruntho, Jonathan G.
Hopkins, Mark R.
Murphy, Stephanie Murphy
Cahaya, Hendry
Blecha, Joseph E.
Jivan, Salma
Cyril, Barinka
Jones, Ella F.
VanBrocklin, Henry F.
Berkman, Clifford E.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 : S379 - S379
[25] Lesion detection with the second generation, 18F-labeled prostate-specific membrane antigen (PSMA)-targeted radiotracer DCFPyL
Rowe, Steven
Szabo, Zsolt
Macura, Katarzyna
Antonarakis, Emmanuel
Eisenberger, Mario
Holt, Daniel
Dannals, Robert
Mease, Ronnie
Pomper, Martin
Cho, Steve
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
[26] Targeting prostate-specific membrane antigen (PSMA) with 18F-labeled compounds: The influence of prosthetic groups on tumor uptake
Bouvet, Vincent
Wuest, Melinda
Bailey, Justin J.
Bergman, Cody
Janzen, Nancy
Valliant, John F.
Wuest, Frank
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 : S81 - S81
[27] Synthesis and evaluation of 18F-labeled trifluoroborate derivatives of PSMA-617 for imaging prostate cancer with positron emission tomography
Kuo, H.
Pan, J.
Merkens, H.
Lau, J.
Zhang, C.
Colpo, N.
Perrin, D. M.
Lin, K.
Benard, F.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S293 - S293
[28] First-in-man analysis of [18F]DCFPyL, a second generation, 18F-labeled PSMA-targeted radiotracer, in patients with metastatic prostate cancer
Mena, Esther
Szabo, Zsolt
Rowe, Steven
Antonarakis, Emmanuel
Eisenberger, Mario
Carducci, Michael
Vranesic, Melin
Mease, Ronnie
Cho, Steve
Pomper, Martin
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
[29] Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination
Naka, Sadahiro
Watabe, Tadashi
Kurimoto, Kenta
Uemura, Motohide
Soeda, Fumihiko
Neels, Oliver C.
Kopka, Klaus
Tatsumi, Mitsuaki
Kato, Hiroki
Nonomura, Norio
Shimosegawa, Eku
Cardinale, Jens
Giesel, Frederik L.
Hatazawa, Jun
EJNMMI RADIOPHARMACY AND CHEMISTRY, 2020, 5 (01)
[30] Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
Treglia, Giorgio
Annunziata, Salvatore
Pizzuto, Daniele A.
Giovanella, Luca
Prior, John O.
Ceriani, Luca
CANCERS, 2019, 11 (05)

← 1 2 3 4 5 →